The anti-IL1 drug canakinumab has been administered in a patient with a high-penetrance T50M TNFRSF1A variant: this experience has been discussed in this manuscript.

Cantarini, L., Lopalco, G., Vitale, A., Caso, F., Lapadula, G., Iannone, F., Galeazzi, M., Rigante, D., Delights and let-downs in the management of tumor necrosis factor receptor-associated periodic syndrome: the canakinumab experience in a patient with a high-penetrance T50M TNFRSF1A variant, <<INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES>>, 2015; 2015 (Maggio): 473-475. [doi:10.1111/1756-185X.12521] [http://hdl.handle.net/10807/68774]

Delights and let-downs in the management of tumor necrosis factor receptor-associated periodic syndrome: the canakinumab experience in a patient with a high-penetrance T50M TNFRSF1A variant

Rigante, Donato
2015

Abstract

The anti-IL1 drug canakinumab has been administered in a patient with a high-penetrance T50M TNFRSF1A variant: this experience has been discussed in this manuscript.
Inglese
Cantarini, L., Lopalco, G., Vitale, A., Caso, F., Lapadula, G., Iannone, F., Galeazzi, M., Rigante, D., Delights and let-downs in the management of tumor necrosis factor receptor-associated periodic syndrome: the canakinumab experience in a patient with a high-penetrance T50M TNFRSF1A variant, <<INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES>>, 2015; 2015 (Maggio): 473-475. [doi:10.1111/1756-185X.12521] [http://hdl.handle.net/10807/68774]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/68774
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 6
social impact